RU2005131724A - Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке - Google Patents
Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке Download PDFInfo
- Publication number
- RU2005131724A RU2005131724A RU2005131724/15A RU2005131724A RU2005131724A RU 2005131724 A RU2005131724 A RU 2005131724A RU 2005131724/15 A RU2005131724/15 A RU 2005131724/15A RU 2005131724 A RU2005131724 A RU 2005131724A RU 2005131724 A RU2005131724 A RU 2005131724A
- Authority
- RU
- Russia
- Prior art keywords
- testosterone
- dose
- group
- composition according
- branched
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims 16
- 229960003604 testosterone Drugs 0.000 title claims 12
- 210000002966 serum Anatomy 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 testosterone ester Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 4
- 239000004359 castor oil Substances 0.000 claims 4
- 235000019438 castor oil Nutrition 0.000 claims 4
- 239000006184 cosolvent Substances 0.000 claims 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- 238000010255 intramuscular injection Methods 0.000 claims 3
- 239000007927 intramuscular injection Substances 0.000 claims 3
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims 3
- 229960000746 testosterone undecanoate Drugs 0.000 claims 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 206010052649 Primary hypogonadism Diseases 0.000 claims 2
- 206010059594 Secondary hypogonadism Diseases 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 229960002903 benzyl benzoate Drugs 0.000 claims 2
- 125000005534 decanoate group Chemical class 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical class CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical class CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 150000003515 testosterones Chemical class 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical class CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 2
- 206010011498 Cryptorchism Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 201000010789 Spermatic Cord Torsion Diseases 0.000 claims 1
- 206010043356 Testicular torsion Diseases 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000000160 cryptorchidism Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (17)
1. Композиция в форме для внутримышечной инъекции, содержащая сложный эфир тестостерона, который выбран из группы сложных эфиров, включающей линейные и разветвленные С9-С16-алканоаты; и носитель, содержащий касторовое масло в концентрации менее 45 об.% и сорастворитель.
2. Композиция по п.1, в которой сложный эфир тестостерона выбран из группы сложных эфиров тестостерона, включающей линейные и разветвленные нонканоаты, деканоаты, ундеканоаты, додеканоаты, тридеканоаты, тетрадеканоаты, пентадеканоаты и гексадеканоаты.
3. Композиция по п.2, в которой сложный эфир тестостерона представляет собой ундеканоат тестостерона.
4. Композиция по п.3, в которой ундеканоат тестостерона присутствует в дозе от 150 до 500 мг/мл.
5. Композиция по п.3, в которой носитель содержит касторовое масло в концентрации менее 40 об.%.
6. Композиция по одному из предыдущих пунктов, в которой сорастворитель представляет собой бензилбензоат.
7. Применение композиции по одному из пп.1-6 в мужской контрацепции.
8. Применение сложного эфира тестостерона, выбранного из группы сложных эфиров, которая включает линейные и разветвленные C9-C16-алканоаты, для приготовления лекарственного средства для лечения первичного и вторичного гипогонадизма у мужчины, причем лекарственное средство находится в форме, предназначенной для внутримышечной инъекции, и содержит носитель, включающий касторовое масло в концентрации менее 45 об.% и сорастворитель.
9. Применение по п.8, в котором первичный гипогонадизм вызван нарушением тестикулярной функции, выбранной из группы нарушений, обусловленных крипторхидизмом, билатеральным тестикулярным перекрутом, орхитом, орхидэктомией, синдромом Кляйнфелтера, химиотерапией или токсическим повреждением, вызванным алкоголем или тяжелыми металлами.
10. Применение по п.8, в котором вторичный гипогонадизм вызван идиопатическим дефицитом гонадотропин-рилизинг-гормона (ГРГ) или повреждением гипофиза-гипоталамуса, обусловленным опухолями, травмой или облучением.
11. Применение сложного эфира тестостерона, выбранного из группы сложных эфиров, которая включает линейные и разветвленные C9-C16-алканоаты, для приготовления лекарственного средства для лечения заболеваний и симптомов, связанных с недостаточными уровнями тестостерона у мужчины, который подвергается лечению прогестином или подавляющим гонадотропин агентом, причем лекарственное средство находится в форме, предназначенной для внутримышечной инъекции, и содержит носитель, включающий касторовое масло в концентрации менее 45 об.% и сорастворитель.
12. Применение по п.11, в котором указанные недостаточные уровни тестостерона у мужчины характеризуются тем, что концентрация тестостерона в сыворотке составляет менее 10 нмолей/л.
13. Применение по любому из пп.7-12, в котором сложный эфир тестостерона выбран из группы сложных эфиров тестостерона, включающей линейные и разветвленные нонканоаты, деканоаты, ундеканоаты, додеканоаты, тридеканоаты, тетрадеканоаты, пентадеканоаты и гексадеканоаты.
14. Применение по п.13, в котором сложный эфир тестостерона представляет собой ундеканоат тестостерона.
15. Применение по п.14, в котором лекарственное средство содержит 6-недельную дозу, составляющую от 500 до 2000 мг, 9-недельную дозу, составляющую от 500 до 2000 мг, 10-недельную дозу, составляющую от 500 до 2000 мг, 11-недельную дозу, составляющую от 500 до 2000 мг, 12-недельную дозу, составляющую от 500 до 2000 мг, 13-недельную дозу, составляющую от 500 до 2000 мг, 14-недельную дозу, составляющую от 500 до 2000 мг, 15-недельную дозу, составляющую от 500 до 2000 мг, или 16-недельную дозу, составляющую от 500 до 2000 мг сложного эфира тестостерона.
16. Применение по п.15, в котором указанная 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- и 16-недельная доза составляет от 750 до 1500 мг.
17. Применение по п.14, в котором сорастворитель представляет собой бензилбензоат.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300399 | 2003-03-14 | ||
| DKPA200300399 | 2003-03-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007118196/15A Division RU2007118196A (ru) | 2003-03-14 | 2007-05-16 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005131724A true RU2005131724A (ru) | 2006-05-10 |
| RU2354381C2 RU2354381C2 (ru) | 2009-05-10 |
Family
ID=32748728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131724/15A RU2354381C2 (ru) | 2003-03-14 | 2004-03-15 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
| RU2007118196/15A RU2007118196A (ru) | 2003-03-14 | 2007-05-16 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007118196/15A RU2007118196A (ru) | 2003-03-14 | 2007-05-16 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US7718640B2 (ru) |
| EP (2) | EP1457208B9 (ru) |
| JP (1) | JP4680891B2 (ru) |
| KR (2) | KR100882378B1 (ru) |
| CN (2) | CN101884639A (ru) |
| AR (1) | AR043603A1 (ru) |
| AT (1) | ATE336251T1 (ru) |
| AU (1) | AU2004218893B2 (ru) |
| BR (2) | BR122017008910A8 (ru) |
| CA (1) | CA2518910C (ru) |
| CL (1) | CL2004000527A1 (ru) |
| CO (1) | CO5700724A2 (ru) |
| CR (1) | CR7999A (ru) |
| CY (1) | CY1105794T1 (ru) |
| DE (1) | DE602004001893T2 (ru) |
| DK (1) | DK1457208T3 (ru) |
| EA (1) | EA011568B1 (ru) |
| EC (1) | ECSP056095A (ru) |
| ES (1) | ES2271772T3 (ru) |
| HR (1) | HRP20050781B1 (ru) |
| IL (1) | IL170473A (ru) |
| IS (1) | IS2565B (ru) |
| JO (1) | JO2505B1 (ru) |
| ME (2) | ME00149B (ru) |
| MX (1) | MXPA04002395A (ru) |
| NO (1) | NO335179B1 (ru) |
| NZ (1) | NZ542321A (ru) |
| PE (1) | PE20041065A1 (ru) |
| PL (1) | PL1457208T3 (ru) |
| PT (1) | PT1457208E (ru) |
| RS (1) | RS51537B (ru) |
| RU (2) | RU2354381C2 (ru) |
| SA (1) | SA04250040B1 (ru) |
| SI (1) | SI1457208T1 (ru) |
| TW (1) | TWI345976B (ru) |
| UA (1) | UA82510C2 (ru) |
| UY (1) | UY28231A1 (ru) |
| WO (1) | WO2004080383A2 (ru) |
| ZA (2) | ZA200508313B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152858A1 (en) * | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| EP1871384A4 (en) | 2005-04-15 | 2012-01-25 | Clarus Therapeutics Inc | SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| WO2010094623A1 (en) | 2009-02-18 | 2010-08-26 | Bayer Schering Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| JP6457383B2 (ja) * | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | テストステロン組成物の針支援式ジェット注入投与 |
| MX367123B (es) * | 2012-05-09 | 2019-08-06 | Univ Western Health Sciences | Formulaciones de pruebas de testosterona proliposomal. |
| WO2014093818A2 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| PT2953667T (pt) * | 2013-02-11 | 2020-01-28 | Antares Pharma Inc | Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida |
| TW201521731A (zh) * | 2013-03-15 | 2015-06-16 | 利波辛股份有限公司 | 用於口服之脂平衡的長鏈睪固酮酯 |
| WO2015023557A1 (en) | 2013-08-12 | 2015-02-19 | Nanomedical Systems, Inc. | Device and method for sustained release of low water solubility therapeutic agent in solubilizer |
| EA201692083A1 (ru) | 2014-04-16 | 2017-03-31 | Вейкс-Фарма Гмбх | Фармацевтическая композиция для ветеринарии и ее применение |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| CN105056115A (zh) * | 2015-08-05 | 2015-11-18 | 成都市飞龙水处理技术研究所 | 一种治疗化脓性睾丸炎的内服药物及其制备方法 |
| EP3544614B1 (en) | 2016-11-28 | 2025-12-31 | Lipocine Inc. | ORAL TREATMENT BASED ON TESTOSTERONE UNDECANOATE |
| US11311554B2 (en) | 2018-04-04 | 2022-04-26 | Slayback Pharma Llc | Pharmaceutical compositions of testosterone |
| CA3107214A1 (en) | 2018-07-20 | 2020-01-23 | Lipocine Inc. | Liver disease |
| KR102051808B1 (ko) * | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
| BR112021011525A2 (pt) * | 2018-12-14 | 2021-08-31 | Acerus Biopharma Inc. | Derivados de éster ativo de testosterona, composições e usos dos mesmos |
| US12083130B2 (en) * | 2019-10-03 | 2024-09-10 | Caren Pharmaceuticals, Inc. | Combination hormone formulations and therapies |
| CA3184810A1 (en) * | 2020-06-11 | 2021-12-16 | Ash Stevens, Llc | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
| US12257257B2 (en) * | 2023-07-27 | 2025-03-25 | Lipocine, Inc. | Testosterone dodecanoate compositions and methods |
| KR20250176964A (ko) * | 2024-06-13 | 2025-12-22 | 주식회사 종근당 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164520A (en) | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| US4181721A (en) | 1975-10-27 | 1980-01-01 | Schering Aktiengesellschaft | Depot preparations in an oily, unsaturated solution for intramuscular injection |
| DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
| GB1567515A (en) | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| US4242863A (en) * | 1978-03-16 | 1981-01-06 | Caterpillar Tractor Co. | Dual phase fuel vaporizing combustor |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5364632A (en) | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| CN1102095A (zh) | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| CA2312898C (en) * | 1997-12-03 | 2004-05-11 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated castor oil |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| EP1087986B1 (en) | 1998-06-19 | 2002-04-10 | Akzo Nobel N.V. | 7.alpha.-methyl 19-nortestosterone undecanoate with androgenic activity |
| BR0009465A (pt) | 1999-04-01 | 2002-01-08 | Akzo Nobel Nv | Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno |
| EE200200454A (et) * | 2000-02-15 | 2003-12-15 | Schering Aktiengesellschaft | Noretisterooni sisaldav meeste kontratseptiivne preparaat |
| US20050101517A1 (en) * | 2000-08-23 | 2005-05-12 | Henrick De Nijs | Novel testosterone ester formulation for human use |
-
2004
- 2004-03-11 JO JO200428A patent/JO2505B1/en active
- 2004-03-12 US US10/798,780 patent/US7718640B2/en active Active
- 2004-03-12 MX MXPA04002395A patent/MXPA04002395A/es active IP Right Grant
- 2004-03-12 UY UY28231A patent/UY28231A1/es not_active Application Discontinuation
- 2004-03-12 TW TW093106693A patent/TWI345976B/zh not_active IP Right Cessation
- 2004-03-15 BR BR122017008910A patent/BR122017008910A8/pt not_active Application Discontinuation
- 2004-03-15 WO PCT/IB2004/000716 patent/WO2004080383A2/en not_active Ceased
- 2004-03-15 AR ARP040100843A patent/AR043603A1/es not_active Application Discontinuation
- 2004-03-15 CN CN2010102249063A patent/CN101884639A/zh active Pending
- 2004-03-15 CA CA002518910A patent/CA2518910C/en not_active Expired - Lifetime
- 2004-03-15 EP EP04075804A patent/EP1457208B9/en not_active Expired - Lifetime
- 2004-03-15 BR BRPI0400214A patent/BRPI0400214A8/pt not_active Application Discontinuation
- 2004-03-15 ES ES04075804T patent/ES2271772T3/es not_active Expired - Lifetime
- 2004-03-15 CL CL200400527A patent/CL2004000527A1/es unknown
- 2004-03-15 SI SI200430105T patent/SI1457208T1/sl unknown
- 2004-03-15 EA EA200501819A patent/EA011568B1/ru unknown
- 2004-03-15 PE PE2004000272A patent/PE20041065A1/es active IP Right Grant
- 2004-03-15 AU AU2004218893A patent/AU2004218893B2/en not_active Expired
- 2004-03-15 HR HRP20050781AA patent/HRP20050781B1/hr not_active IP Right Cessation
- 2004-03-15 DK DK04075804T patent/DK1457208T3/da active
- 2004-03-15 ME MEP-2008-145A patent/ME00149B/me unknown
- 2004-03-15 KR KR1020057017087A patent/KR100882378B1/ko not_active Expired - Lifetime
- 2004-03-15 RS YUP-2005/0702A patent/RS51537B/sr unknown
- 2004-03-15 AT AT04075804T patent/ATE336251T1/de active
- 2004-03-15 CN CN200480006912.4A patent/CN1761469B/zh not_active Expired - Lifetime
- 2004-03-15 DE DE602004001893T patent/DE602004001893T2/de not_active Expired - Lifetime
- 2004-03-15 UA UAA200509571A patent/UA82510C2/ru unknown
- 2004-03-15 KR KR1020087025443A patent/KR20080096717A/ko not_active Withdrawn
- 2004-03-15 RU RU2005131724/15A patent/RU2354381C2/ru active
- 2004-03-15 NZ NZ542321A patent/NZ542321A/en not_active IP Right Cessation
- 2004-03-15 PL PL04075804T patent/PL1457208T3/pl unknown
- 2004-03-15 ME MEP-145/08A patent/MEP14508A/xx unknown
- 2004-03-15 PT PT04075804T patent/PT1457208E/pt unknown
- 2004-03-15 EP EP06016949A patent/EP1743646A3/en not_active Withdrawn
- 2004-03-15 JP JP2006506335A patent/JP4680891B2/ja not_active Expired - Lifetime
- 2004-03-21 SA SA04250040A patent/SA04250040B1/ar unknown
-
2005
- 2005-08-24 IL IL170473A patent/IL170473A/en active IP Right Grant
- 2005-09-20 CR CR7999A patent/CR7999A/es not_active Application Discontinuation
- 2005-10-07 CO CO05102559A patent/CO5700724A2/es not_active Application Discontinuation
- 2005-10-12 IS IS8069A patent/IS2565B/is unknown
- 2005-10-12 EC EC2005006095A patent/ECSP056095A/es unknown
- 2005-10-13 NO NO20054711A patent/NO335179B1/no unknown
- 2005-10-13 ZA ZA200508313A patent/ZA200508313B/en unknown
-
2006
- 2006-11-16 CY CY20061101678T patent/CY1105794T1/el unknown
-
2007
- 2007-01-02 ZA ZA200700046A patent/ZA200700046B/xx unknown
- 2007-05-16 RU RU2007118196/15A patent/RU2007118196A/ru not_active Application Discontinuation
-
2009
- 2009-02-24 US US12/391,655 patent/US8338395B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005131724A (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
| JP2006520377A5 (ru) | ||
| US10940205B2 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| CN1248738C (zh) | 用于人的睾酮酯制剂 | |
| CN101605529B (zh) | 稳定制剂及它们的制备和使用方法 | |
| CA2842177C (en) | Formulations of deoxycholic acid and salts thereof | |
| CN109862881A (zh) | 用于注射装置的药物氢化可的松溶液 | |
| CN103118664B (zh) | 环孢菌素乳液 | |
| WO2014118696A2 (en) | Pharmacuetical compositions of rapamycin esters and its derivatives | |
| RU2002124602A (ru) | Композиция для мужской контрацепции, включающая норэтистерон | |
| US3051624A (en) | Long-acting hormone preparations | |
| KR20230167019A (ko) | 이식편 대 숙주 질환의 치료를 위한 조성물 및 방법 | |
| CN1374857A (zh) | 肠胃外用磷雌氮芥和磺烷基醚环化糊精制剂 | |
| CN1177583C (zh) | 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂 | |
| CN117177737A (zh) | 可自乳化的多西他赛注射用组合物及其制备方法 | |
| WO2024224424A1 (en) | Injectable compositions of metolazone | |
| EP4025205A1 (en) | Cabazitaxel liquid formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |